? All had strong results? EPS per share fell $13.88 to $5.84 from 2023 to 2024. Additionally, growth expectations are negative for the next two quarters and more than half less that S&P 500 peers later quarters 2025. JNJ shares have significantly lagged peers over the last five years when looking at equivalent drug and medtech indexes. JNJ needs to continue to rightsize to address pension and health insurance for 130000 employees (which ironically been at that level for two years when they have “cut” 20000 to 30,000) that only escalate in cost. Also, add all the lawsuits that hangover JNJ, they need to find savings somewhere.
